From Lab Innovation to Life-Saving Therapies: Gene Editing Therapeutics Market Poised to Hit US$ 6.26 Billion by 2032, Expanding at a 147.20% CAGR Driven by Rap…

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
BioTechniques

Cryo-EM reveals new aspects of CRISPR-Cas biology

Researchers at Vilnius University (Lithuania) have uncovered how the bacterial protein Cas9, better known as the CRISPR-Cas ...

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...
GEN

Turbocharging Cas9’s Nuclear Entry

Advanced engineered cell therapies require gene editing tools that are both precise and efficient. In recent years, CRISPR-Cas9 has emerged as the gold standard for editing genes with greater ...
TMCnet

ERS Genomics launches new Early Access Express License

New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...
University of California, Davis

A Gene Editor That's a Better Fit for Plants

Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...
MarketBeat on MSN

CRISPR Therapeutics gains after earnings as pipeline hope grows

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...